Colchicine (anti-inflammatory)

inflammation redox

Approved medicine for another condition in 8 of 9 markets tracked.

1 randomized trial (111 people, 2 days). It found no effect on its main endpoint.

Doses studied: 1.5 mg on day 1, then 1 mg on day 2.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (8)

T7 Pascart 2023 Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial doi:10.1016/S2665-9913(23)00165-0
T5 Cipolletta 2025 Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospitalisation, and mortality data doi:10.1016/S2665-9913(24)00248-0
T5 Tseng 2026 Effect of Colchicine Use and Usual Care Alone on the Rate of Progression to Chronic Kidney Disease and Mortality in Patients with Heat-Related Injury doi:10.3390/healthcare14060744
T5 Manenti 2021 Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study doi:10.1371/journal.pone.0248276
T3 Mohammadi Jouabadi 2026 Colchicine Alleviates Non-Atherosclerotic Vascular Aging by Targeting Endothelial Dysfunction and Inflammatory Status doi:10.2147/jir.s538430
T3 Iatcenko 2026 Colchicine Protects Against Sickle Cell Related Cardiomyopathy: Evidence of the Novel Role of Inflammaging doi:10.3390/antiox15080912
TX Sanghavi 2022 Impact of colchicine on mortality and morbidity in COVID-19: a systematic review doi:10.1080/07853890.2021.1993327
TX Yang 2010 Oral Colchicine (Colcrys) in the Treatment and Prophylaxis of Gout: Profile Report doi:10.2165/11206330-000000000-00000